Neoadjuvant chemoradiation therapy is a commonly used option aimed to make less aggressive surgery approaches and to improve quality of life allowing a high proportion of patients operated with sphincter-sparing surgical techniques in locally advanced rectal cancer (LARC). During the last 5 years a number of studies have tested the efficacy of more intensive chemotherapeutic approaches by combining irinotecan or oxaliplatin with fluoropyrimidines and standard radiation treatments as well as testing combined treatments with targeted agents directed against epidermal growth factor receptor (EGFR) or angiogenesis. Herein, we review the results and critiques of the published studies based on the introduction of novel targeted agents in neoadjuvant therapy of LARC.

Torino, F., Sarmiento, R., Gasparini, G. (2013). The contribution of targeted therapy to the neoadjuvant chemoradiation of rectal cancer. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 87(3), 283-305 [10.1016/j.critrevonc.2013.02.002.].

The contribution of targeted therapy to the neoadjuvant chemoradiation of rectal cancer.

TORINO, FRANCESCO;
2013-01-01

Abstract

Neoadjuvant chemoradiation therapy is a commonly used option aimed to make less aggressive surgery approaches and to improve quality of life allowing a high proportion of patients operated with sphincter-sparing surgical techniques in locally advanced rectal cancer (LARC). During the last 5 years a number of studies have tested the efficacy of more intensive chemotherapeutic approaches by combining irinotecan or oxaliplatin with fluoropyrimidines and standard radiation treatments as well as testing combined treatments with targeted agents directed against epidermal growth factor receptor (EGFR) or angiogenesis. Herein, we review the results and critiques of the published studies based on the introduction of novel targeted agents in neoadjuvant therapy of LARC.
2013
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/06 - ONCOLOGIA MEDICA
English
Con Impact Factor ISI
Targeted therapy; Bevacizumab; Cetuximab; Rectal cancer; Neoadjuvant-treatment.
http://www.sciencedirect.com/science/article/pii/S1040842813000450
Torino, F., Sarmiento, R., Gasparini, G. (2013). The contribution of targeted therapy to the neoadjuvant chemoradiation of rectal cancer. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 87(3), 283-305 [10.1016/j.critrevonc.2013.02.002.].
Torino, F; Sarmiento, R; Gasparini, G
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Torino et al. CROH-03.2013.pdf

accesso aperto

Descrizione: Articolo principale
Dimensione 621.61 kB
Formato Adobe PDF
621.61 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/101155
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 8
social impact